RaQualia Pharma Inc.: what insiders have been doing
RaQualia Pharma Inc. is a Health Care company. Its directors and officers file their transactions with EDINET (Japan FSA). The last twelve months, up to 10 November 2026, brought 4 filings signed by 2 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Compared with its exchange (3,419 companies, median 3 filings), a count of 4 filings is above the norm.
There has been no open-market purchase by an insider of RaQualia Pharma Inc. for at least a year. The median gap between trade and publication is zero days: most filings appear on the same day. This delay matters because a trade only becomes useful information once it is public.
For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. Source: insider filings from EDINET (Japan FSA). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 49.9% of flowShareXTKSEDINET:S100XECF
- 52.6% of flowShareXTKSEDINET:S100XI19
- 22.3% of flowShareXTKSEDINET:S100X8GI
- 50.1% of flowShareXTKSEDINET:S100X8QH
- 100.0% of flowShareXTKSEDINET:S100VHOX
- 25.1% of flowShareXTKSEDINET:S100VEXR
- 2.0% of flowShareXTKSEDINET:S100VGYP
- 98.0% of flowShareXTKSEDINET:S100PXBH
8 of 8 declarations
About RaQualia Pharma Inc.
Rakuaria Pharmaceutical Co., Ltd. is a company focused on the research and development of new drugs. It specializes in innovative treatments in the healthcare and pharmaceutical sector.
